Jacobs & Co. CA boosted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 9.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 97,506 shares of the pharmaceutical company’s stock after purchasing an additional 8,241 shares during the quarter. Jacobs & Co. CA’s holdings in GlaxoSmithKline were worth $3,902,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of GSK. Sunbelt Securities Inc. acquired a new position in shares of GlaxoSmithKline in the 2nd quarter valued at approximately $213,000. Coastal Investment Advisors Inc. raised its position in shares of GlaxoSmithKline by 6.1% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 15,756 shares of the pharmaceutical company’s stock valued at $630,000 after buying an additional 911 shares in the last quarter. Wedbush Securities Inc. raised its position in shares of GlaxoSmithKline by 13.5% in the 2nd quarter. Wedbush Securities Inc. now owns 54,165 shares of the pharmaceutical company’s stock valued at $2,168,000 after buying an additional 6,443 shares in the last quarter. Waldron Private Wealth LLC raised its position in shares of GlaxoSmithKline by 9.2% in the 2nd quarter. Waldron Private Wealth LLC now owns 6,080 shares of the pharmaceutical company’s stock valued at $245,000 after buying an additional 512 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its position in shares of GlaxoSmithKline by 1.8% in the 2nd quarter. CIBC Private Wealth Group LLC now owns 14,824 shares of the pharmaceutical company’s stock valued at $593,000 after buying an additional 261 shares in the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

GSK has been the subject of several analyst reports. Cowen restated a “hold” rating and issued a $45.00 target price on shares of GlaxoSmithKline in a research report on Monday, June 10th. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Thursday, April 25th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday. Finally, Morgan Stanley restated an “underweight” rating on shares of GlaxoSmithKline in a research report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $42.66.

Shares of GlaxoSmithKline stock traded down $0.59 during midday trading on Wednesday, hitting $40.06. 58,458 shares of the company traded hands, compared to its average volume of 2,607,786. The stock has a market capitalization of $99.60 billion, a PE ratio of 12.71, a price-to-earnings-growth ratio of 1.97 and a beta of 0.71. The company has a debt-to-equity ratio of 7.86, a quick ratio of 0.48 and a current ratio of 0.71. The business has a fifty day simple moving average of $40.90. GlaxoSmithKline plc has a 12 month low of $36.41 and a 12 month high of $42.47.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.14. The company had revenue of $10.04 billion for the quarter, compared to analyst estimates of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. As a group, equities research analysts predict that GlaxoSmithKline plc will post 2.91 earnings per share for the current year.

In related news, Director Plc Glaxosmithkline purchased 333,333 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were bought at an average cost of $15.00 per share, with a total value of $4,999,995.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: What is meant by buying and selling pressure?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.